Randomized phase II trial of adjuvant chemotherapy with vinorelbine plus cisplatin versus S-1 plus carboplatin in patients with completely resected stage II/IIIA non-small cell lung cancer
Phase 2
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000008165
- Lead Sponsor
- Fukushima medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Contraindication with S-1, carboplatin, vinorelbine and cisplatin 2) With large cell neuroendocrine carcinoma(LCNEC) 3) With interstitial pneumonitis or pulmonary fibrosis detectable on chest X-ray 4) With double cancer, multiple cancer 5) With Serious post-operative complications 6) With severe drug allergies 7) With serious concurrent disease 8) With serious diarrhea 9) Current use of flucytosine 10) Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 11) Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two year relapse-free survival rate
- Secondary Outcome Measures
Name Time Method Overall Survival Relapse-free Survival Completion rate of protocol treatment Safety